HenryFriedmanMD

Neurosurgery • Durham, NC

Professor of Neuro-Oncology, Duke University

Join to view full profile

Dr. Friedman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Friedman's full profile

Already have an account?

Office
2100 Erwin Rd
Durham, NC 27705
Phone+1 919-620-4467

Fax+1 919-684-6674

Summary

Dr. Henry Friedman is a neuro-oncologist in Durham, NC and is affiliated with Duke University Hospital. He received his medical degree from State University of New York Upstate Medical University and has been in practice 40 years. He is experienced in the treatment of children and adults with brain and spinal cord tumors

Education & Training

Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1981 - 1983
SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1979 - 1980
SUNY Upstate Medical UniversityResidency, Pediatrics, 1977 - 1979
SUNY Upstate Medical UniversityClass of 1977

Certifications & Licensure

NC State Medical License 1983 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Elected Member The American Society for Clinical Investigation, 1994

Clinical Trials

Carboplatin in Patients With Progressive Gliomas Start of enrollment: 1993 Feb 01
Completed
Phase 2
Melphalan in Patients With Neoplastic Meningitis Start of enrollment: 1992 Dec 01
Completed
Phase 1
Chemotherapy in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 1997 Feb 01
Completed
Phase 1
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma Start of enrollment: 1997 Apr 01
Completed
Phase 1
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain Start of enrollment: 1998 May 01
Completed
Phase 1
Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors Start of enrollment: 1998 Apr 01
Completed
Phase 1
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas Start of enrollment: 1998 Jul 01
Completed
Phase 1
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme Start of enrollment: 1997 Sep 01
Completed
Phase 2
Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Start of enrollment: 1998 Mar 01
Completed
Phase 2
Temozolomide in Treating Patients With Progressive Low-Grade Glioma Start of enrollment: 1998 Mar 01
Completed
Phase 2
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Start of enrollment: 1998 Jan 01
Completed
Phase 2
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma Start of enrollment: 2000 Aug 01
Completed
Phase 1
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Start of enrollment: 2000 Aug 01
Completed
Phase 1, Phase 2
Temozolomide in Treating Patients With Brain Metastases Start of enrollment: 2000 Aug 01
Completed
Phase 2
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Start of enrollment: 2000 Aug 01
Completed
Phase 2
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma Start of enrollment: 2001 Mar 01
Completed
Phase 1
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse Start of enrollment: 2001 Jun 01
Completed
Phase 2
Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

255 citations
Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
Michael R. Zalutsky, David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman
Journal of Nuclear Medicine. 2008-01-01
3780 citations
IDH1 and IDH2 Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin, Roger E. McLendon, B.K. Ahmed Rasheed
The New England Journal of Medicine. 2009-02-19
478 citations
Recurrent glioblastoma treated with recombinant poliovirus
Annick Desjardins, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi
The New England Journal of Medicine. 2018-06-26

Journal Articles

The Genomic Landscape of TERT Promoter Wildtype-IDH Wildtype Glioblastoma
Daniel B. Loriaux, Darel D. Bigner, Fausto J. Rodriguez, Hai Yan, Bil H. Diplas, Henry S. Friedman, Roger E. McLendon, Nature